Imaging Department, Service of Biostatistics and Epidemiology, and Medical Department, Institut Gustave Roussy, Villejuif Cedex, France.
Clin Cancer Res. 2010 Feb 15;16(4):1216-25. doi: 10.1158/1078-0432.CCR-09-2175. Epub 2010 Feb 9.
To determine the utility of dynamic contrast-enhanced ultrasonography (DCE-US) as a prognostic tool for metastatic renal cell carcinoma patients receiving sunitinib and to identify DCE-US parameters that correlate with early treatment response.
Thirty-eight patients received 50 mg/d sunitinib on schedule 4/2 (4 weeks on followed by 2 weeks off treatment). After two cycles, response evaluation criteria in solid tumors were used to classify patients as responders or nonresponders. DCE-US evaluations were done before treatment and at day 15; variations between days 0 and 15 were calculated for seven DCE-US functional parameters and were compared for responders and nonresponders. The correlation between DCE-US parameters and disease-free survival (DFS) and overall survival (OS) was assessed.
The ratio between DCE-US examinations at baseline and day 15 significantly correlated with response in five of the seven DCE-US parameters. Two DCE-US parameters (time to peak intensity and slope of the wash-in) were significantly associated with DFS; time to peak intensity was also significantly associated with OS.
DCE-US is a useful tool for predicting the early efficacy of sunitinib in metastatic renal cell carcinoma patients. Robust correlations were observed between functional parameters and classic assessments, including DFS and OS.
确定动态对比增强超声（DCE-US）作为接受舒尼替尼治疗的转移性肾细胞癌患者的预后工具的效用，并确定与早期治疗反应相关的 DCE-US 参数。
38 名患者按计划接受 50mg/d 舒尼替尼治疗，4/2 方案（4 周治疗后 2 周停药）。两个周期后，采用实体瘤反应评估标准将患者分为应答者和无应答者。在治疗前和第 15 天进行 DCE-US 评估；计算 0 天和 15 天之间的七个 DCE-US 功能参数的变化，并比较应答者和无应答者之间的变化。评估 DCE-US 参数与无病生存期（DFS）和总生存期（OS）的相关性。
在基线和第 15 天的 DCE-US 检查之间的比值与五个 DCE-US 参数中的五个参数的反应显著相关。两个 DCE-US 参数（达峰时间和洗脱斜率）与 DFS 显著相关；达峰时间也与 OS 显著相关。
DCE-US 是预测转移性肾细胞癌患者舒尼替尼早期疗效的有用工具。功能参数与经典评估之间存在稳健的相关性，包括 DFS 和 OS。
